度普利尤单抗与沙利度胺治疗成人难治性结节性痒疹的疗效及安全性比较

打开文本图片集

中图分类号R969.4；R751 文献标志码A 文章编号 1001-0408（2025）21-2687-05

DOI 10.6039/j.issn.1001-0408.2025.21.12

ABSTRACTOBJECTIVETocompare theeffcacyandsafetyofdupilumab versus thalidomide inthetreatmentof refractory prurigo nodularis（（PN）inadults.METHODSAretrospectiveanalysis wasconductedontheclinicaldataof123adult patients with refractoryPNadmitedtoWuhanFirst Hospital from May2021toJune2024.Among them，63 patients whoreceiveddupilumab comprisedtheobservationgroupand60patientswhoreceivedthalidomidecomprisedthecontrolgroup.Clinicaleficacyindicators [InvestigatorGlobal Assessment（IGA）score，Pruritus NumericalRating Scale（P-NRS）score，Patient-OrientedEczemaMeasure （POEM）score，andDermatologyLifeQualityIndex（DLQI）score]，allrgic biomarkers[eosinophil（EOS）countinperipheral blood andserumtotalimmunoglobulinE（IgE）level]，psychological scores[HospitalAnxietyandDepresionScale（HADS）] beforeandaftertreatment，aswellastheoccurenceof adversedrugreaction during treatment，werecomparedbetweenthe two groups.RESULTSBeforetreatment，therewerenostisicallysignificantdiferencesbetweenthetwogroups inaboveclinical effcacy indicators，allergic biomarkers，or psychological scores （ （P>0.05 ）.At 4，8，12 and 16 weeks after treatment，both groups showed significant decreases inIGAscore（exceptforthecontrol group4 weks aftertreatment），IGAactivityscore（exceptfor thecontrol group4weeksaftertreatment），P-NRSscore，POEMscore，DLQIscore（except forthecontrol group4 weeksafter treatment），serum EOS count，and serum total IgE level compared with baseline （ ⋅P<0.05 ）；at12 and 16 weeks after treatment， scores onboththe HADS-anxietysubscaleand HADS-depresionsubscale werealsosignificantlylowerthanbaselineinbothgroups 0 ⋅P<0.05 ）；the observation group was significantly lower than the control group （ ⋅<0.05 ）.The overall incidence of adverse events was 12.70% in the observation group，which was significantly lower than 28.33% in the control group P<0.05） CONCLUSIONS Dupilumabtreatment inadultswithrefractoryPNdemonstratessuperioreficacycompared with thalidomidein improvingskinlesions，relieving pruritus，reducingperipheralEOScountsandserumtotal IgE，andimprovingqualityoflifeand psychological status，while showing a more favorable safety profile.

KEYWORDSprurigo nodularis；dupilumab； thalidomide; skin lesion；pruritus；quality of life；psychological status; efficacy; safety

结节性痒疹（prurigo nodularis，PN）是一种慢性、复发性皮肤病，以顽固性瘙痒及四肢伸侧多发性皮肤结节为主要临床特征。（剩余9969字）